Assignee
JOUNCE THERAPEUTICS INC
US·10 granted patents·16 pending applications·32 citations·filing 2015–2022
Top patents by PatentIndex Score
26 records- 0191US11905329B2Anti-PD-1 antibodies and uses thereofJOUNCE THERAPEUTICS INC·Filed 2022·Granted Feb 20, 2024·1 cites·35 claims
- 0289US10626176B2Methods of treating conditions with antibodies that bind B7-H4JOUNCE THERAPEUTICS INC·Filed 2015·Granted Apr 21, 2020·8 cites·2 claims
- 0387US10654929B2Antibodies to PD-1 and uses thereofJOUNCE THERAPEUTICS INC·Filed 2017·Granted May 19, 2020·3 cites·36 claims
- 0487US10023635B2Antibodies to ICOSJOUNCE THERAPEUTICS INC·Filed 2016·Granted Jul 17, 2018·8 cites·47 claims
- 0583US11384147B2Anti-PD-1 antibodies and uses thereofJOUNCE THERAPEUTICS INC·Filed 2020·Granted Jul 12, 2022·1 cites·72 claims
- 0682US10570203B2Antibodies to ICOSJOUNCE THERAPEUTICS INC·Filed 2018·Granted Feb 25, 2020·3 cites·24 claims
- 0781US10723798B2Antibodies to LILRB2JOUNCE THERAPEUTICS INC·Filed 2018·Granted Jul 28, 2020·3 cites·21 claims
- 0880US11292840B2Methods of treating cancer in a subject having elevated ICOS and/or T-bet levels of CD+4 cells by administering an ICOS agonistJOUNCE THERAPEUTICS INC·Filed 2019·Granted Apr 5, 2022·3 cites·19 claims
- 0980US10968277B2Gene signatures for determining ICOS expressionJOUNCE THERAPEUTICS INC·Filed 2016·Granted Apr 6, 2021·2 cites·21 claims
- 1069US2023053631A1Antibodies to lilrb2JOUNCE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1165US11359019B2Antibodies to LILRB2JOUNCE THERAPEUTICS INC·Filed 2020·Granted Jun 14, 2022·0 cites·24 claims
- 1264US2021171635A1Antibodies to ICOSJOUNCE THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1362US2022332823A1Methods of treating cancerJOUNCE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1460US2022281978A1Compositions and Methods for the Treatment of Cancer (Anti-ICOS Antibody Dosing)JOUNCE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1559US2020207856A1Antibodies to lilrb2JOUNCE THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1657US2021340256A1Gene Signatures for Determining ICOS ExpressionJOUNCE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1754US2022378909A1Methods of Treating Cancer with Anti-PD-1 AntibodiesJOUNCE THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1852US2023151098A1Compositions and Methods for Vaccination and the Treatment of Infectious DiseasesJOUNCE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1949US2022135682A1Anti-ICOS Antibodies for the Treatment of CancerJOUNCE THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2046US2022289847A1Methods for the treatment of cancerJOUNCE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2145US2020024351A1Compositions and Methods for the Treatment of CancerJOUNCE THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2244US2021353750A1Methods of Treating CancerJOUNCE THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2344US2021355222A1Methods of Treating CancerJOUNCE THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2442US2021380942A1Methods and compositions for the treatment of cancer and infectious diseasesJOUNCE THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2538US2023089426A1Methods for the treatment of cancerJOUNCE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2631US2016200815A1Antibodies that inhibit tim-3:lilrb2 interactions and uses thereofJOUNCE THERAPEUTICS INC·Filed 2016·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →